REal World Data in LYmphoma and Survival in Adults

Launched by HOSPICES CIVILS DE LYON · Mar 8, 2019

Keywords

ClinConnect Summary

The REal World Data in LYmphoma and Survival in Adults trial, also known as the REALYSA cohort, is studying how different types of lymphoma affect patients over time. This trial aims to gather important information about what factors might influence how well patients respond to treatment, the challenges they face after treatment, and their overall quality of life. By collecting real-life data from patients with various types of lymphoma, including diffuse large B-cell lymphoma and Hodgkin's lymphoma, the researchers hope to better understand the disease and improve patient care.

To be eligible for this trial, participants need to be over 18 years old and have been diagnosed with lymphoma within the last six months. They should not have received any major anti-lymphoma treatments yet, although some medications used before treatment may be allowed. Participants can expect to share their health information over the course of the study, which will help doctors learn more about lymphoma and how to support patients better. This trial is currently recruiting, and people of all genders are welcome to join.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Signature of the consent form for participation in the REALYSA cohort
• • Aged over 18 at the time of inclusion
• • Diagnosed with lymphoma in the last 6 months (180 days)
• • Lymphoma subtype belonging to at least one of the 7 histological subtypes: diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, T-cell lymphoma, Hodgkin's lymphoma, Burkitt lymphoma
• Exclusion Criteria:
• • Anti-lymphoma treatment already received (except pre-phase: typically corticosteroids, vincristine, cyclophosphamide, etoposide, alone or in combination)
• • Documented HIV infection
• * Any other lymphoma subtype not included in the list in Appendix 1. Of note, are excluded:
• • Chronic lymphocytic leukemia/small lymphocytic lymphoma
• • Hairy cell leukemia and variant
• • Lymphoplasmacytic lymphoma
• • Waldenström macroglobulinemia
• • Primary DLBCL of the central nervous system (CNS)
• • T-cell large granular lymphocytic leukemia
• • Chronic lymphoproliferative disorder of NK cells
• • Mycosis fungoides
• • Sézary syndrome
• • Primary cutaneous T cell lymphomas (mainly diagnosed and treated by dermatologists)
• • Post-transplant lymphoproliferative disorders (PTLD)